MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

911.16 +24.53 (+2.77%)
Streaming Delayed Price Updated: 12:05 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout ↗
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline. 
Via Benzinga
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY).... 
Via Finterra
Topics Economy Intellectual Property
Eli Lilly & Co (NYSE:LLY): A Prime Dividend Growth Candidate Backed by Strong Profitability ↗
Via Chartmill
News headline image
Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket ↗
The takeover fills a glaring hole in Eli Lilly's pipeline, says one analyst. 
Via Investor's Business Daily
News headline image
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗
There are some tempting bargains if you know where to look. 
Via The Motley Fool
News headline image
Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
Via MarketBeat
News headline image
Stock Market Today, March 30: High Oil Prices Drive Risk-Off Sentiment, Nasdaq Falls 0.7% ↗
Inflation and growth worries impacted tech stocks as investors question AI price tags today, March 30, 2026. 
Via The Motley Fool
Topics Artificial Intelligence Bonds Economy
News headline image
Eli Lilly's CEO Says This Could Be a Game Changer for Its Business ↗
The healthcare stock may not be running out of growth catalysts anytime soon. 
Via The Motley Fool
News headline image
Nervous About the Market? 3 Vanguard ETFs That Were Made for Times Like These. ↗
You can sleep peacefully at night owning these Vanguard ETFs. 
Via The Motley Fool
Topics Bonds ETFs Economy
News headline image
Prediction: Buying Pfizer Stock Today Could Set You Up for Life ↗
Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Secures $2.75 Billion Deal With Insilico Medicine To Bring AI-Developed Drugs To Global Market: Report ↗
Eli Lilly's deal involves an upfront payment of $115 million to Insilico, with additional payments tied to milestones. 
Via Benzinga
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate. 
Via The Motley Fool
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Eli Lilly is much more than just a weight loss stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
Via MarketMinute
News headline image
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? ↗
It's not much of a contest right now. 
Via The Motley Fool
News headline image
Corporate Fortress: S&P 500 Defies Gravity with Fifth Consecutive Quarter of Double-Digit Growth
The American corporate engine has proven far more durable than even the most optimistic analysts predicted just a year ago. As of March 27, 2026, final results for the fourth quarter of 2025 have... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Institutional Investors Are Selling One of Wall Street's Premier Trillion-Dollar Club Members (No, Not Nvidia!) ↗
This critical cog of the artificial intelligence (AI) supply chain was notably reduced by Wall Street's savviest money managers and passive funds during the fourth quarter. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
1 Vanguard Index Fund to Buy Before It Soars 129%, According to a Wall Street Strategist ↗
Tom Lee, a veteran Wall Street strategist, says the S&P 500 could hit 15,000 by 2030. 
Via The Motley Fool
Topics ETFs Retirement Stocks
News headline image
Could Buying Eli Lilly Today Set You Up for Life? ↗
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which... 
Via MarketMinute
News headline image
Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The Steel-Walled Resurgence: How Foreign Capital and Policy Are Powering a New U.S. Industrial Golden Age
The United States is currently witnessing a structural pivot of historic proportions, as the long-heralded "U.S. Industrial Renaissance" moves from a policy ambition to a tangible, factory-floor... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Is the Vanguard Dividend Appreciation ETF a Buy Now? ↗
This ETF has struggled so far this year. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
The Vanguard Fund That Can Turn $400 Per Month Into More Than $1.5 Million ↗
Even if you're starting with $0 today, you can still build up a million-dollar portfolio with regular monthly investments. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF ↗
After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026. 
Via The Motley Fool
Topics ETFs
News headline image
Regional Bank Stock Up 33% as $3.7 Million Exit Tells a Different Story ↗
First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story